Lannett Company, Inc. (NYSE MKT: LCI) today reported continued strong momentum, with sharply improved financial results for its fiscal 2013 second quarter ended December 31, 2012, compared with the prior year period.
Net sales for the fiscal 2013 second quarter rose significantly to $36.6 million, up 32% from $27.7 million last year. Gross profit nearly doubled to $13.4 million from $7.4 million for the fiscal 2012 second quarter. As a percentage of net sales, gross margin increased to 37% from 27% last year. Research and development (R&D) expenses were $3.6 million, compared with $2.5 million for the fiscal 2012 second quarter. Selling, general and administrative (SG&A) expenses were $5.2 million, compared with $4.4 million in the same quarter of the prior year. Operating income increased to $4.7 million from $495,000 for the second quarter of fiscal 2012. Net income attributable to Lannett Company rose to $2.9 million, or $0.10 per diluted share, from $609,000, or $0.02 per diluted share, for the same period last year.
“The positive performance for our second quarter and the favorable outlook for the second half of our fiscal year reflect continued strong sales from our base products and market penetration from our recently approved products,” said Arthur Bedrosian, president and chief executive officer of Lannett. “Gross margin was positively impacted by favorable sales mix and price increases, along with enhanced manufacturing efficiencies that are partially attributable to recent product launches. We believe Lannett’s R&D investments, which are ratcheting up as the year proceeds, combined with the operating momentum we are now achieving, will pave the way for continued growth and progress in the future,” Bedrosian added.
For the first half of fiscal 2013, net sales increased to $71.9 million from $56.6 million for the corresponding prior year period. Gross profit rose to $27.0 million from $16.0 million last year. As a percentage of net sales, gross margin increased to 38% from 28% last year. R&D expenses were $7.3 million, compared with $4.9 million for the first six months of fiscal 2012. SG&A expenses amounted to $11.3 million, versus $9.2 million for the first half of fiscal 2012. Operating income advanced to $8.4 million from $1.9 million a year ago. Net income attributable to Lannett Company increased to $5.8 million, equal to $0.20 per diluted share, from $815,000, or $0.03 per diluted share, for the first half of fiscal 2012. Net income for the most recent six-month period included a favorable litigation settlement of $1.3 million and other non-operating items, equal to $0.03 per diluted share.
Upward Revised Guidance for Fiscal 2013
Based on Lannett’s current outlook, the company revised its financial guidance upward for the fiscal 2013 full year as follows:
Conference Call Information and Forward-Looking Statements
Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for the fiscal 2013 second quarter ended December 31, 2012. The conference call will be available to interested parties by dialing 866-813-5647 from the U.S. or Canada, or 847-619-6249 from international locations, passcode 34177997. The conference call will also be available through a live audio Internet broadcast at www.lannett.com. A playback of the call will be archived and accessible at this site for at least three months.
Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company’s financial status and performance and regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.
About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company’s website at www.lannett.com.
This news release contains certain statements of a forward-looking nature relating to future events or future business performance.Any such statements, including, but not limited to, achieving the financial metrics stated in the company’s upward revised guidance, expected product approvals, the successful commercialization of products in development, product applications pending at the FDA and recently approved products, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time.These forward-looking statements represent the company's judgment as of the date of this news release.The company disclaims any intent or obligation to update these forward-looking statements.
|LANNETT COMPANY, INC. AND SUBSIDIARIES|
|CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)|
|(In thousands, except for share and per share data)|
|Three months ended||Six months ended|
|December 31,||December 31,|
|Cost of sales||22,620||19,771||43,784||39,513|
|Amortization of intangible assets||470||470||941||938|
|Research and development expenses||3,572||2,513||7,336||4,939|
|Selling, general, and administrative expenses||5,155||4,419||11,326||9,164|
|Other income (expense):|
|Foreign currency gain (loss)||-||(8||)||3||(3||)|
|Gain (loss) on sale of assets||(112||)||(3||)||(42||)||4|
|Realized gain (loss) on investments||132||27||96||(146||)|
|Unrealized gain (loss) on investments||(61||)||675||209||(151||)|
|Interest and dividend income||27||36||62||89|
|Income before income tax expense||4,608||1,149||9,828||1,583|
|Income tax expense||1,749||519||4,026||731|
|Less net income (loss) attributable to noncontrolling interest||22||(21||)||5||(37||)|
|Net income attributable to Lannett Company, Inc.||$||2,881||$||609||$||5,807||$||815|
|Earnings per common share - Lannett Company, Inc.:|
|Weighted average number of shares outstanding:|
|LANNETT COMPANY, INC. AND SUBSIDIARIES|
|CONSOLIDATED BALANCE SHEETS|
|(In thousands, except share and per share data)|
December 31, 2012
June 30, 2012
|Cash and cash equivalents||$||31,455||$||22,562|
|Trade accounts receivable (net of allowance of $111 and $124, respectively)||41,370||42,212|
|Prepaid income taxes||249||2,120|
|Deferred tax assets||4,955||4,833|
|Other current assets||1,309||1,023|
|Total Current Assets||116,664||106,481|
|Property, plant and equipment, net||38,876||37,068|
|Intangible assets, net||3,488||4,429|
|Deferred tax assets||8,540||9,069|
|Accrued payroll and payroll related||3,810||3,198|
|Current portion of long-term debt||654||648|
|Rebates, chargebacks and returns payable||18,961||17,039|
|Total Current Liabilities||44,032||40,392|
|Long-term debt, less current portion||6,255||6,513|
|Commitment and Contingencies|
Common stock - authorized 50,000,000 shares, par value $0.001; issued, 28,822,773 and 28,594,437 shares, respectively; outstanding, 28,386,894 and 28,252,192 shares, respectively
|Additional paid in capital||100,913||99,515|
|Accumulated other comprehensive loss||(26||)||(63||)|
|Treasury stock at cost - 435,879 and 342,245 shares, respectively||(2,034||)||(1,594||)|
|Total Shareholders' Equity Attributable to Lannett Company, Inc.||117,925||111,123|
|TOTAL SHAREHOLDERS' EQUITY||118,091||111,313|
|TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY||$||168,378||$||158,218|
Last updated on: 08/02/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.